Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Description

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Conditions

HER2-Positive Breast Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Condition
HER2-Positive Breast Carcinoma
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Post-menopausal women with hormone receptor positive breast cancer. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.
  • * 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.
  • * 25 women who will be starting Tamoxifen (comparative group)
  • * 25 healthy post menopausal women will also be recruited.
  • * Established diagnosis of diabetes
  • * Therapy with medications that could affect glucose metabolism
  • * Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5%
  • * History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication

Ages Eligible for Study

to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mayo Clinic,

Kalpana Muthusamy, MBBS, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

2025-12-01